Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cross-linked carboxymethylcellulose (CX-CMC) is a chemically modified derivative of cellulose, engineered to enhance its performance characteristics such as thermal stability, resistance to salt, and thickening efficiency. It is prized for its excellent water retention, viscosity control, and stabilizing properties. In pharmaceutical applications, CX-CMC is utilized in ophthalmic solutions for conditions like Dry Eye Disease, where it provides viscoelastic, hydrating, and wound healing benefits. It also serves as a biosynthetic filler for soft-tissue augmentation, offering volume and structural support. Additionally, it is widely used as an excipient in various pharmaceutical formulations, including as a disintegrant in tablets and in advanced drug delivery systems.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cross-linked carboxymethylcellulose.